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ABSTRACT
Background. Neutrophil-lymphocyte ratio (NLR), plate-
let-lymphocyte ratio (PLR), and lymphocyte-monocyte
ratio (LMR) may serve as a simple index of the immune
function. The aim of this study was to investigate the
prognostic significance of NLR, PLR, and LMR in patients
with resectable pancreatic ductal adenocarcinoma (PDAC)
and to verify whether such biomarkers are associated with
changes in populations of lymphoid cells.
Methods. The prognostic implications of blood count
parameters were evaluated in a retrospective cohort of 442
subjects undergoing pancreatic resections for PDAC.
Subpopulations of lymphocytes and monocytes in periph-
eral blood were identified by FACS in a prospective cohort
of 54 patients.
Results. In the univariate analysis, NLR\ 5 and LMR C 3
were associated with significantly longer median survival of
25.7 vs 12.6 months and 29.2 vs 13.1 months, respectively.
PLR did not influence survival. The Cox proportional hazards
model showed that high NLR (HR 1.66, 95 % CI 1.12 to 2.46,
P = 0.012) and low LMR (HR 1.65, 95 % CI 1.06 to 2.58,
P = 0.026) were independent predictors of poor prognosis.
NLR C 5 and LMR\ 3 correlated with an approximately
twofold decrease in counts of helper and cytotoxic T cells, B
cells, and NK cells. High NLR was also accompanied with
increased neutrophil counts, while low LMR showed
increased numbers of monocytes, mostly classical.
Conclusions. NLR and LMR may carry important prog-
nostic information for patients with resected PDAC. The
unfavorable prognosis likely correlates with reduced
numbers of immune cells effective against the tumor and
increased populations of cells involved in immune
suppression.
The functional status of the immune system significantly
affects the prognosis of many human malignancies,
including gastrointestinal cancers.1 The tumor-related
response of a host defense system is associated with rear-
rangements of various hematological components, such as
white blood cells, specifically the neutrophils, lymphocytes
and monocytes. Recently, several investigators suggested
that variables derived from routine blood count parameters,
i.e. platelet-lymphocyte ratio (PLR) and neutrophil-lym-
phocyte ratio (NLR), could serve as a simple index of the
immune function and may be of prognostic significance in
patients with solid tumors.2,3 This observation is of con-
siderable clinical importance as many laboratory tests used
previously to examine the inflammatory machinery are
expensive or labor-intensive, and thus not suitable for
routine clinical practice.
High values of two parameters incorporating lympho-
cyte count, i.e. NLR and PLR, have been previously
reported as possibly associated with impaired survival of
patients with resectable pancreatic cancer.4,5 Although the
proposed biomarkers might prove useful in stratifying
patients with good and poor prognosis, they have not yet
been appropriately validated for clinical decision making
as almost all of these studies recruited relatively small
populations.6,7 Moreover, it is not known what are the
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mechanisms implicated in the correlation between blood
counts and patients’ survival.
The aim of this study was to investigate the prognostic
significance of routine lymphocyte-based blood count
parameters, such as neutrophil-lymphocyte ratio, platelet-
lymphocyte ratio, and lymphocyte-monocyte ratio in
patients with resectable pancreatic cancer. Moreover, we
sought to verify whether prognostically important values of
such biomarkers are associated with changes in populations
of lymphoid cells.
MATERIALS AND METHODS
Patients
The study was carried out in 2 separate cohorts of
treatment naı̈ve patients with pancreatic ductal adenocar-
cinoma (PDAC). The prognostic implications of blood
count parameters were evaluated in a retrospective cohort
including subjects undergoing pancreatic resections
between 1990 and 2012 for PDAC at our academic tertiary
surgical center. A prospective cohort for experiments
examining populations of immune cells in peripheral blood
consisted of a group of 54 consecutive PDAC patients
recruited between 2012 and 2014. Patients with prior
neoadjuvant treatment as well as active infection, hema-
tological disorders, acute and chronic inflammatory or
autoimmune diseases, or prior steroid therapy were
excluded. All data were prospectively collected and
recorded in a dedicated database. Variables potentially
affecting survival were retrieved from the database and
analyzed retrospectively, including demographic data,
pathologic features of the tumor, and therapeutic inter-
ventions. The extent of surgery was classified as defined by
the recent guidelines.8,9 Tumors were evaluated according
to the current American Joint Committee on Cancer
(AJCC) classification criteria.10 R0 resections were
assumed if all tumor-free margins were at least 1 mm
wide.11 The study was approved by the Bioethics Com-
mittee of Jagiellonian University.
Blood Count Parameters
All samples of peripheral blood were collected within
10 days prior to surgery (prospective and retrospective
cohorts). The patients were required to have preoperative
blood counts along with differential white blood cell count,
including neutrophils, lymphocytes, monocytes, and pla-
telets. NLR and PLR were calculated as the absolute count
of neutrophils and platelets, respectively, divided by the
absolute lymphocyte count. Similarly, LMR was defined as
the ratio of the lymphocyte count to the absolute count of
monocytes.
Identification of Lymphatic Cells in Peripheral Blood
Peripheral whole blood samples were collected in sterile
BD Vacutainer EDTA (ethylenediamine-tetraacetic acid)
blood collection tubes (BD Biosciences). The samples were
incubated in BD TrucountTM tubes (BD Biosciences) with
the following monoclonal antibodies to identify lympho-
cyte sub-populations (BD Biosciences): anti-CD45-PerCP
(clone 2D1), anti-CD3-FITC (clone UCHT-1), anti-CD4-
APC (clone RPA-T4), anti-CD8-PE (clone RPA-T8), anti-
CD16-PE (clone 3G8), anti-CD19-APC (clone HIB19),
anti-CD56-PE (clone NCAM16.2). The following anti-
bodies were used for monocyte sub-populations (BD
Biosciences): anti-CD45-APC (clone 2D1), anti-HLA-DR-
PerCP (clone L243), anti-CD14-FITC (clone M5E2), and
anti-CD16-PE (clone 3G8). The samples were incubated at
4 C for 30 min and then were treated with FACS Lysing
Solution (BD Biosciences) until the erythrocytes were
lysed and the cells were immediately processed in the
FACSCanto flow cytometer (Becton–Dickinson Immuno-
cytometry Systems, Palo Alto, CA) along with 10,000
beads per tube. The results were analyzed with FACSDiva
Software (BD Biosciences) and the absolute numbers of
lymphocytes and monocytes subsets were calculated on the
basis of bead counts. Monocyte populations were classified
as classical (CD14?? CD16-), intermediate (CD14??
CD16?), and non-classical (CD14? CD16??).12
Statistical Analysis
All continuous variables are reported with their median
and interquartile range (IQR) while categorical data are
reported as proportions. Statistical significances of the
differences in categorical and continuous variables were
analyzed by v2 and Mann–Whitney U tests where appro-
priate. Survival data was analyzed according to the
Kaplan–Meier method and included postoperative mortal-
ity. The prognostic value of each blood count parameter
was tested as raw, continuous data by the Cox regression
analysis and as categorical variables with the optimum cut-
off values identified with the time-dependent ROC curves
analysis.13 Multivariate analysis was performed using a
Cox proportional hazards model with a backward stepwise
selection procedure. The probability for entering the model
was 0.05 and for removal from the model 0.100. All tests
were two-sided and P\ 0.050 was considered statistically
significant. Statistical analysis was performed using the
IBM SPSS Statistics 20 software package (IBM Cor-
poration, NY).
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RESULTS
Patient Characteristics
A total of 536 patients who underwent pancreatic
resections for PDAC were identified in the database
between 1990 and 2012. Detailed blood count parameters
were available in 442 patients, and they constituted the
final population for the retrospective cohort (Table 1).
There were 260 males and 182 females with a median age
of 60 years (range 21–83). The prospective cohort recrui-
ted 54 patients with similar clinicopathologic
characteristics. There were no significant differences
between these two cohorts except for higher proportions of
patients subject to pylorus-preserving pancreaticoduo-
denectomy and postoperative chemotherapy in the
prospective group. No neoadjuvant therapy was used in
either population and all the patients were free of recent or
ongoing infection based on clinical signs and symptoms
along with laboratory parameters.
TABLE 1 Clinicopathologic characteristics of the study population
Parameter Cohort
Retrospective (n = 442) Prospective (n = 54)
Age, years (median, IQR) 60 (55–66) 59 (50–68)
Female/male (n, %) 182 (41)/260 (59) 25 (46)/29 (54)
Body mass index (median, IQR) 23.3 (21.3–26.1) 22.6 (20.4–26.9)
WBC, 109/L (median, IQR) 6.915 (5.745–8.560) 7.725 (5.930–8.430)
Neutrophils, 109/L (median, IQR) 4.25 (3.36–5.67) 5.20 (3.30–6.40)
Lymphocytes, 109/L (median, IQR) 1.75 (1.28–2.22) 1.64 (1.20–2.07)
Monocytes, 109/L (median, IQR) 0.590 (0.480–0.850) 0.700 (0.500–0.900)
Platelets, 109/L (median, IQR) 249 (200–326) 248 (198–319)
Neutrophil-lymphocyte ratio (median, IQR) 3.0 (2.0–4.1) 2.9 (2.2–3.7)
Lymphocyte-monocyte ratio (median, IQR) 3.3 (2.3–5.0) 2.7 (1.7–3.5)
Platelet-lymphocyte ratio (median, IQR) 149 (105–208) 156 (129–247)
Preoperative endoscopic biliary drainage, n (%) 121 (27) 17 (31)
Procedure (n, %)
Pancreaticoduodenectomy (PD) 146 (33) 18 (33)
Pylorus preserving PD 107 (24) 21 (39)
Distal pancreatectomy 101 (23) 12 (22)
Total pancreatectomy 88 (20) 3 (6)
Tumor size, mm (median, IQR) 30 (25–40) 28 (22–44)
Perineural invasion, n (%) 292 (66) 34 (62)
Lymphovascular invasion, n (%) 339 (77) 39 (72)
Tumor differentiation, n (%)
Well-differentiated 43 (10) 6 (11)
Moderately/poorly differentiated 399 (90) 48 (89)
AJCC stage (n, %)
IA 18 (4) 3 (6)
IB 29 (7) 5 (9)
IIA 103 (23) 12 (22)
IIB 283 (64) 33 (61)
III 9 (2) 1 (2)
Resection margin, n (%)
R0 226 (51) 29 (54)
R1/R2 210 (48)/6 (1) 24 (44)/1 (2)
Postoperative chemotherapy, n (%) 235 (53) 42 (78)
IQR interquartile range
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Blood Count Parameters
The median (IQR) values of blood count parameters are
shown in Table 1. There were no significant differences in
individual parameters between the retrospective and
prospective patient cohorts. A correlation analysis failed to
identify any association between blood count parameters
and tumor characteristics, including tumor size, perineural
invasion, lymphovascular invasion, grade, and TNM cate-
gories. There were no associations between blood counts
and margin positivity. Moreover, blood count parameters
did not influence rates of postoperative infective compli-
cations and mortality.
Predictive Factors for Survival
Prognostic factors were analyzed in the retrospective
cohort. Sixty-four of 442 patients were alive after a median
follow-up of 93 months (range 15-290 months, final fol-
low-up December 2015). The overall median survival was
19.2 months (95 % CI 14.1–24.2) with 3-year and 5-year
survival rates of 28 and 16 %, respectively. Table 2 shows
the results of the univariate analysis of potential prognostic
factors. Among the three evaluated blood count parame-
ters, the platelet-lymphocyte ratio did not influence
survival either as a continuous or categorical variable. The
neutrophil-lymphocyte ratio and lymphocyte-monocyte
ratio were associated with survival and the time-dependent
ROC curves analysis identified the best cut-off values to
stratify patients into low and high risks of 5 and 3 for NLR
and LMR, respectively. The overall median survival of
patients with NLR C 5 (n = 119) was significantly shorter
than those with lower values of this ratio (12.6 vs
25.7 months, P = 0.001, Fig. 1a). Better median survival
(29.2 vs 13.1 months, P = 0.001) was also found for high
LMR values (LMR C 3, n = 247, Fig. 1b). Subsequently,
the Cox proportional hazards model showed that high NLR
(HR 1.66, 95 % CI 1.12–2.46, P = 0.012) and low LMR
(HR 1.65, 95 % CI 1.06–2.58, P = 0.026) were indepen-
dent predictors of poor prognosis.
Correlation of NLR and LMR with Changes
in Lymphocyte and Monocyte Sub-populations
The hypothesis that NLR and LMR are associated with
changes in lymphocyte and monocyte sub-populations was
verified in the prospective cohort of patients. Twenty-two
(41 %) patients showed low values of both NLR and LMR,
17 (31 %) had LMR C 3, and elevated NLR was found in
15 (28 %) subjects. No patient demonstrated high values of
TABLE 2 Univariate and multivariate Cox proportional analysis for overall survival
Parameter Categoriesa Univariate analysis Multivariate analysis
HR (95 % CI) Pb HR (95 % CI) Pc
Age \65/C65 years 1.45 (1.07–1.96) 0.016 1.74 (1.19–2.55) 0.004
Gender Female/male 1.07 (0.80–1.43) 0.662 –
NLR \5, C5 1.58 (1.12–2.72) 0.001 1.66 (1.12–2.46) 0.012
LMR C3,\3 1.93 (1.19–3.11) 0.001 1.65 (1.06–2.58) 0.026
CA 19-9 level \180/[ 180 U/mL 1.04 (0.68–1.41) 0.623 –
Tumor location Head/other 1.09 (0.77–1.54) 0.599 –
Tumor size \20/C20 mm 1.08 (0.74–1.58) 0.675 –
Perineural invasion No/yes 1.41 (1.06–1.89) 0.018 1.32 (0.75–2.31) 0.332
Lymphovascular invasion No/yes 0.98 (0.59–1.60) 0.935 –
Tumor differentiation Well/other 1.36 (0.81–2.28) 0.237 –
AJCC T category T1–2/T3–T4 2.25 (1.23–4.09) 0.008 2.90 (0.73–11.42) 0.127
AJCC N category N0/N1 1.57 (1.13–2.17) 0.007 1.75 (1.090–2.79) 0.019
Metastatic lymph node ratio \0.2; C0.2 1.92 (1.39–2.65) \0.001 1.69 (1.10–2.60) 0.016
AJCC stage I/II and III 1.86 (1.01–3.45) 0.049 2.96 (0.79–13.94) 0.337
Resection margin R0/R1 and 2 2.17 (1.51–3.11) \0.001 2.16 (1.16–4.02) 0.015
Chemotherapy Yes/no 0.94 (0.61–1.45) 0.794 –
CI confidence interval, HR hazard ratio, NLR neutrophil-lymphocyte ratio, LMR lymphocyte-monocyte ratio
a Reference category listed first
b Log Rank Mantel–Cox test
c Cox proportional hazards model
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both parameters. Table 3 shows the absolute counts of
lymphocyte and monocyte populations according to the
groups with high and low values of NLR and LMR. There
were no significant differences in the proportions of T cells
(78 %, IQR 73–81), helper T cells (47 %, IQR 40–53),
cytotoxic T cells (24 %, IQR 20–33), B cells (9 %, IQR
7–10), and natural killer cells (12 %, IQR 8–17) in either
group. However, the absolute counts differed significantly.
NLR C 5 was associated with nearly two-fold lower counts
of all lymphocyte subpopulations. The group with low
LMR (\3) showed similar alterations and additionally had
elevated counts of all monocyte subsets compared to
patients with LMR C 3.
DISCUSSION
Alterations in blood count parameters reflect the
dynamic balance between anti-tumor and tumor-promoting
functions of the immune system. The neutrophil-lympho-
cyte ratio and lymphocyte-monocyte ratio, simple
derivatives of routine blood counts, were identified as
important prognostic indicators in a large population
dataset of patients with resected pancreatic cancer. More-
over, we have demonstrated that both these parameters are
associated with changes in some populations of lympho-
cyte and monocyte subsets.
The idea of using inflammation-related prognostic
scores utilizing blood count parameters has gained
increasing attention in the treatment of various gastroin-
testinal malignancies, including pancreatic cancer.14–17
This was substantiated by the fact that such parameters
were also associated with impaired survival in patients with
advanced pancreatic cancer,18,19 including those receiving
palliative chemotherapy20,21 and stereotactic body
TABLE 3 Median (interquartile range) counts of lymphocyte and monocyte populations in groups with various NLR and LMR
Cell phenotype Population NLR LMR
\5 C5 \3 C3
Neutrophils Neutrophils 4250 (3257–6140) 6090 (4700–7570)* 4900 (3250–6200) 5300 (4000–7900)
Lymphocytes overall Lymphocytes 1839 (1462–2550) 928 (484–1156)* 1316 (1026–1760) 2360 (1787–3948)*
CD3? T cells 1384 (1007–1833) 761 (371–966)* 985 (788–1308) 1655 (1384–3055)*
CD3 ?/CD4? Helper T cells 797 (654–1252) 466 (271–581)* 589 (466–981) 808 (716–1811)*
CD3 ?/CD8? Cytotoxic T cells 421 (299–717) 244 (158–319)* 306 (223–373) 717 (485–1071)*
CD19? B cells 164 (137–211) 66 (37–96)* 128 (66–180) 170 (137–211)*
CD16 ? 56 NK cells 266 (148–314) 75 (40–143)* 174 (103–264) 314 (117–576)*
CD14 ?? CD16- Monocytes, classical 669 (371–945) 512 (370–649) 659 (520–929) 395 (275–566)*
CD14 ?? CD16? Monocytes, intermediate 26 (15–34) 22 (11–34) 29 (18–42) 23 (11–29)*
CD14 ? CD16 ?? Monocytes, non-classical 43 (30–56) 35 (25–55) 49 (35–59) 34 (24–45)*
* P\ 0.05 Mann–Whitney U test
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FIG. 1 Kaplan–Meier curves of overall survival according to blood
count parameters. a Neutrophil-lymphocyte ratio—NLR (log-rank
test P = 0.001). b Lymphocyte-monocyte ratio—LMR (log-rank test
P = 0.001)
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radiotherapy.22 Nevertheless, previous reports of resected
pancreatic cancer were not uniform and were convoluted by
some common problems, such as low number of patients,
unclear selection of cut-off values,23–25 or concomitant
evaluation of resectable and unresectable disease.26
Table 4 summarizes previous studies reporting prog-
nostic applications of the three main parameters related to
blood counts, i.e. NLR, LMR, and PLR. The majority of
studies focused on NLR and the recruitment of large
patient cohorts, including our findings, helped to show that
high neutrophil-lymphocyte ratios (either C2, C3 or C5)
significantly increased the risk of death. Although the
precise mechanism is not completely understood, multi-
factorial effects of neutrophilia are postulated.27 An
increased production of neutrophils is associated with
higher proportions of immature cells and altered functional
status. These changes are hypothesized to create an
immunosuppressive milieu impairing the performance of
the effector immune cells and promoting more aggressive
growth of the tumor.28
Monocytes are another important player involved in
human malignancies. Although it is not yet certain which
subset of the circulating monocyte pool, i.e. classical or
non-classical, is recruited into the microenvironment as the
main source of tumor-associated macrophages, these cells
can exert local immunosuppressive effects promoting
tumor growth and angiogenesis.29 Both high monocyte
counts and low lymphocyte-to-monocyte ratios have been
reported to be predictors of poor survival in patients with
solid tumors.30 However, the importance of lymphocyte-to-
monocyte ratio was evaluated only in a few studies
recruiting patients with resectable pancreatic cancer. Li
et al. in a group of 144 curatively-resected pancreatic
cancers showed that LMR C 2.86 was an independent
favorable prognostic factor with HR 0.148 (95 % CI
0.085–0.252).31 Similar observations were reported in
another study recruiting resectable and advanced cancers,
where LMR[ 2.8 reduced the risk of death (HR 0.81,
95 % CI 0.66–0.99, P = 0.040).32
An elevated platelet-lymphocyte ratio was associated
with worse survival in various solid tumors.33 However, in
contrast to NLR and LMR, high values of PLR impaired
survival in only two reports involving small populations of
resectable pancreatic cancer.4,34,35 As the prognostic
implications of PLR were not also demonstrated in unre-
sectable cases, it seems that this parameter is of limited
significance.20
TABLE 4 Summary of previous studies analyzing prognostic applications of NLR, LMR, and PLR in resected pancreatic cancer
Author, year No. of patients Cut-off values* Median survival (months) Multivariate survival analysis HR (95 % CI)
Neutrophil-lymphocyte ratio (NLR)
Clark, 200723 44 \5, C5 10.5/8.9 No effects on survival
Smith, 20094 110 Continuous Not applicable No effects on survival
Bhatti, 20105 84 Continuous Not applicable 1.21 (1.01–1.45), P = 0.039
Jamieson, 201137 135 \5, C5 20.9/25.7 No effects on survival
Garcea, 201138 74 \5, C5 52.0/12.0 No effects on survival
Sanjay, 201239 51 \5, C5 16.2/9.2 No effects on survival
Stotz, 201340 110 \5, C5 Not reported 1.61 (1.02–2.53), P = 0.039
Hamed, 201341 85 \5, C5 20.6/11.3 No effects on survival
Ben, 201542 381 \2, C2 19.4/12.4 1.51 (1.15–1.99), P = 0.003
Watanabe, 201635 46 \2.5, C2.5 Not reported No effects on survival
Current study 442 \5, C5 25.7/12.6 1.66 (1.12–2.46), P = 0.012
Lymphocyte-monocyte ratio (LMR)
Li, 201631 144 \2.86, C2.86 12.0/19.0 0.15 (0.09–0.25), P\ 0.001
Current study 442 C3,\3 29.2/13.1 1.65 (1.06–2.58), P = 0.026
Platelet-lymphocyte ratio (PLR)
Smith, 20094 110 Continuous Not applicable 1.004 (1.002–1.006), P\ 0.001
Bhatti, 20105 84 Continuous Not applicable No effects on survival
Jamieson, 201137 135 \150, C150 26.7/20.7 No effects on survival
Sanjay, 201239 51 150, 150–300, 300 15.9/15.0/4.1 No effects on survival
Stotz, 201340 110 \150, C150 Not reported No effects on survival
Watanabe, 201635 46 \200, C200 Not reported 4.55, P = 0.002
Current study 442 No effects on survival No effects on survival
* Reference category listed first
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In a large and homogenous population of patients with
resectable pancreatic cancer, we have demonstrated that
high NLR and low LMR were associated with impaired
long-term survival. However, unlike previous reports, we
showed that these parameters were related to changes in
populations of immune cells. Values of NLR and LMR
implicated in worse prognosis correlated with an approxi-
mately twofold decrease in counts of all lymphocyte
populations. High NLR was also accompanied by increased
neutrophil counts, while low LMR showed increased
numbers of monocytes, mostly classical. This clearly sug-
gests that the unfavorable prognosis was likely correlated
with reduced numbers of immune cells effective against the
tumor and increased populations of cells involved in
immune suppression.27,36
Our study has two potential limitations. First, lympho-
cyte and monocyte subpopulations were analyzed only in a
small proportion of patients, even though there were no
marked differences in most clinicopathologic parameters
between the prospective and retrospective cohorts. Second,
we did not evaluate the functional status of immune cells
that could also contribute to impaired defense against
cancer beside changes in the absolute counts. Therefore,
future experiments should also consider the functional
characteristics of the immune system in relation to altered
blood counts.
In conclusion, this study demonstrated that variables
obtained from routine blood count parameters may carry
important prognostic information for patients with resected
pancreatic cancer. High neutrophil-lymphocyte and low
lymphocyte-monocyte ratios were associated with unfa-
vorable prognosis. Moreover, both parameters were
associated with marked alterations in the subsets of lym-
phocyte, monocyte, and neutrophil populations, likely
contributing to impaired defense against cancer.
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